Asthma management during COVID and beyond
Asthma management during COVID and beyond
Get access to exclusive content and news updates:

Dr Justus de Zeeuw
Head of Pneumology, Rehabilitation Clinic AmKaRe, Germany
The content of this website has been developed by Napp Pharmaceuticals Limited for UK healthcare professionals only. Napp is responsible for the content of this website and is also the copyright owner/authorised user of the content.
UK-RZF-2400060 | DOP: March 2024
For Healthcare Professionals: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Napp Pharmaceuticals Limited at drugsafetyUKandROI@mundipharma.com.
For General Public: If you experience any side-effects, talk to your doctor, nurse or pharmacist. This includes any possible side-effects not listed in the package leaflet. You can also report side-effects directly via the Yellow Card scheme at www.mhra.gov.uk/yellowcard. By reporting side-effects you can help provide more information on the safety of this medicine.
For Healthcare Professionals: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Napp Pharmaceuticals Limited at drugsafetyUKandROI@mundipharma.com.
For General Public: If you experience any side-effects, talk to your doctor, nurse or pharmacist. This includes any possible side-effects not listed in the package leaflet. You can also report side-effects directly via the Yellow Card scheme at www.mhra.gov.uk/yellowcard. By reporting side-effects you can help provide more information on the safety of this medicine.
Your browser is not supported.
To view this content, please use one of the following browsers:
Head of Pneumology, Rehabilitation Clinic AmKaRe, Germany